Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation EMA Recommends Extension of Indications for Sugemalimab FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma MOST POPULAR NCI-MATCH Update: More Labs, New Arms, and Initial Findings November 15, 2018 Loving Yourself April 7, 2021 Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... December 11, 2020 FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma June 25, 2020 Load more HOT NEWS Today is Random Acts of Kindness Day Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... A urine test for bladder cancer: What’s the latest?
